Tag Archives: Galapagos

November, 2018

28 November
FDA Grants Fast Track Designation to Galapagos’ Investigational Disease-Modifying Osteoarthritis Drug

Mechelen, Belgium; 27 November 2018, 22.01 CET – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that the FDA has granted GLPG1972/S201086 Fast Track designation for the treatment of patients with osteoarthritis (OA). The US Food and Drug Administration’s (FDA’s) Fast Track program is designed to facilitate the development and expedite the …
Share

25 October
AbbVie Assumes Full Development and Commercial Control of Galapagos’ Cystic Fibrosis Assets

NORTH CHICAGO, Ill., Oct. 24, 2018 /PRNewswire/ — AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced today that it will assume full development and commercial responsibility for its collaboration with Galapagos (Euronext: GLPG) to discover and develop new therapies to treat cystic fibrosis (CF). AbbVie’s research program aims to develop a …
Share

31 May
Gilead and Galapagos Announce Positive Results with Filgotinib in Psoriatic Arthritis and Progression into Phase 3 Ulcerative Colitis Study

FOSTER CITY, Calif. & MECHELEN, Belgium–(BUSINESS WIRE)–Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) announced that the randomized, placebo-controlled Phase 2 EQUATOR study of filgotinib, an investigational, selective JAK1 inhibitor, in 131 adults with moderate to severe psoriatic arthritis, achieved its primary endpoint of improvement in …
Share

21 December
Galapagos Reports Positive Results From Its Phase 2 Study of Its Cystic Fibrosis Drug

Mechelen, Belgium; 20 December 2016 – Galapagos NV (Euronext & NASDAQ: GLPG) reports topline results from its SAPHIRA 1 Phase 2 study in cystic fibrosis patients with potentiator GLPG1837. The SAPHIRA 1 trial included 26 patients with the G551D mutation in CFTR each receiving three sequential doses of GLPG1837. Of …
Share

18 December
Gilead Invests up to $2 Billion in Galapagos for its Anti-Inflammatory Drug

MECHELEN, Belgium and FOSTER CITY, Calif., Dec. 17, 2015 (GLOBE NEWSWIRE) — Galapagos NV (Euronext & NASDAQ: GLPG) and Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the companies have entered into a global partnership for the development and commercialization of the JAK1-selective inhibitor filgotinib for inflammatory indications. Galapagos will …
Share

15 April
Galapagos’ Oral Rheumatoid Arthritis Candidate Meets Primary Endpoint in Phase II Study

Belgium-based Galapagos NV said that its oral JAK1 inhibitor, in development for treatment of patients with rheumatoid arthritis (RA), met key endpoints in its mid-stage study. The company’s selective JAK1 inhibitor filgotinib showed improvements in signs and symptoms of active RA and met key efficacy endpoints after 12 weeks of …
Share

17 March
Galapagos and Janssen End Inflammation Alliance

Galapagos NV and Janssen Pharmaceutica NV of Johnson & Johnson have ended their eight-year alliance to develop anti-inflammatory drugs. The companies originally entered into a worldwide multi-target alliance in October 2007, to discover and develop novel small-molecule therapeutics for the treatment of rheumatoid arthritis (RA), a deal which provided Galapagos …
Share